Hims and Hers beats revenue estimates on strong subscriber growth

Core Viewpoint - Hims and Hers Health exceeded Wall Street revenue expectations for Q3, driven by subscriber growth and expanded personalized healthcare offerings [1][2]. Group 1: Financial Performance - The company reported quarterly revenue of $600 million, surpassing analysts' estimates of $580.2 million [2]. - Adjusted profit for the quarter ending September 30 was 6 cents per share, which was below the average analyst estimate of 10 cents per share [2]. - Monthly online revenue per average subscriber increased by 19% to $80 [2]. Group 2: Subscriber Growth - Hims and Hers' subscriber base grew to 2.47 million, marking a 21% increase from the previous year [2]. - The growth in subscribers contributed significantly to the company's revenue performance [2]. Group 3: Market Context - The company has launched personalized versions of semaglutide, a key ingredient in the weight-loss drug Wegovy, in response to government restrictions on mass production of drug copies [1].